Site-specific protein biomarkers in gastric cancer: a comprehensive review of novel biomarkers and clinical applications

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: gLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA A Cancer J Clin. 2021;71(3):209–249. doi: 10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Umeda S, Kanda M, Shimizu D, et al. Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. Gastric Cancer. 2022;25(3):558–572. doi: 10.1007/s10120-022-01284-y
   PubMed Web of Science ®Google Scholar
• Shinozuka T, Kanda M, Ito S, et al. D2 lymph node dissection confers little benefit on the overall survival of older patients with resectable gastric cancer: a propensity score-matching analysis of a multi-institutional dataset. Surg Today. 2020;50(11):1434–1442. doi: 10.1007/s00595-020-02021-7
   PubMed Web of Science ®Google Scholar
• Kanda M, Terashima M, Kinoshita T, et al. A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer. Gastric Cancer. 2023;26(1):108–115. doi: 10.1007/s10120-022-01351-4
   PubMed Web of Science ®Google Scholar
• Roy S, Kanda M, Nomura S, et al. Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer. Mol Cancer. 2022;21(1):42. doi: 10.1186/s12943-022-01527-7
   PubMed Web of Science ®Google Scholar
• Okuno K, Watanabe S, Roy S, et al. A liquid biopsy signature for predicting early recurrence in patients with gastric cancer. Br J Cancer. 2023;128(6):1105–1116. doi: 10.1038/s41416-022-02138-1
   PubMed Web of Science ®Google Scholar
• Shimizu D, Taniue K, Matsui Y, et al. Pan-cancer methylome analysis for cancer diagnosis and classification of cancer cell of origin. Cancer Gene Ther 2021. 2022;29(5):428–436. doi: 10.1038/s41417-021-00401-w
   PubMed Web of Science ®Google Scholar
• Shimura T, Toden S, Kandimalla R, et al. Genomewide Expression Profiling Identifies a Novel miRNA-based Signature for the Detection of Peritoneal Metastasis in Patients with Gastric Cancer. Ann Surg. 2021;274(5):e425–e434. doi: 10.1097/SLA.0000000000003647
   PubMed Web of Science ®Google Scholar
• Izumi D, Zhu Z, Chen Y, et al. Assessment of the Diagnostic Efficiency of a Liquid Biopsy Assay for Early Detection of Gastric Cancer. JAMA Netw Open. 2021;4:e2121129. doi: 10.1001/jamanetworkopen.2021.21129
   PubMed Web of Science ®Google Scholar
• Shimizu D, Kanda M, Kodera Y. Emerging evidence of the molecular landscape specific for hematogenous metastasis from gastric cancer. World J Gastrointest Oncol. 2018;10(6):124–136. doi: 10.4251/wjgo.v10.i6.124
   PubMed Web of Science ®Google Scholar
• Kanda M, Kodera Y. Molecular mechanisms of peritoneal dissemination in gastric cancer. World J Gastroenterol. 2016;22(30):6829–6840. doi: 10.3748/wjg.v22.i30.6829
   PubMed Web of Science ®Google Scholar
• Baniak N, Senger JL, Ahmed S, et al. Gastric biomarkers: a global review. World J Surg Oncol. 2016;14(1):212. doi: 10.1186/s12957-016-0969-3
   PubMedGoogle Scholar
• Ha SY, Lee J, Jang J, et al. HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int J Cancer. 2015;136(7):1629–1635. doi: 10.1002/ijc.29159
   PubMed Web of Science ®Google Scholar
• Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi: 10.1016/S0140-6736(10)61121-X
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–2465. doi: 10.1056/NEJMoa1200694
   PubMed Web of Science ®Google Scholar
• Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients with First-line, Advanced Gastric Cancer: the KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571–1580. doi: 10.1001/jamaoncol.2020.3370
   PubMed Web of Science ®Google Scholar
• Park W, Bang JH, Nam AR, et al. Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients. Cancer Res Treat. 2021;53(1):199–206. doi: 10.4143/crt.2020.497
   PubMed Web of Science ®Google Scholar
• Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008;9(3):279–287. doi: 10.1016/S1470-2045(08)70072-X
   PubMed Web of Science ®Google Scholar
• Oshi M, Murthy V, Takahashi H, et al. Urine as a Source of Liquid Biopsy for Cancer. Cancers (Basel). 2021;13(11):2652. doi: 10.3390/cancers13112652
   PubMed Web of Science ®Google Scholar
• Herrera-Pariente C, Montori S, Llach J, et al. Biomarkers for Gastric Cancer Screening and Early Diagnosis. Biomedicines. 2021;9(10):1448. doi: 10.3390/biomedicines9101448
   PubMed Web of Science ®Google Scholar
• Haffner I, Schierle K, Raimúndez E, et al. HER2 Expression, Test Deviations, and Their Impact on Survival in Metastatic Gastric Cancer: results from the Prospective Multicenter VARIANZ Study. J Clin Oncol. 2021;39:1468–1478.
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Fuchs CS, Tabernero J, et al. Efficacy of Pembrolizumab Monotherapy for Advanced Gastric/Gastroesophageal Junction Cancer with Programmed Death Ligand 1 Combined Positive Score ≥10. Clin Cancer Res. 2021;27:1923–1931.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim JH, Jang HJ, et al. Pathological and Prognostic Impacts of FGFR2 Overexpression in Gastric Cancer: a Meta-Analysis. J Cancer. 2019;10(1):20–27. doi: 10.7150/jca.28204
   PubMed Web of Science ®Google Scholar
• Hagi T, Kurokawa Y, Kawabata R, et al. Multicentre biomarker cohort study on the efficacy of nivolumab treatment for gastric cancer. Br J Cancer. 2020;123(6):965–972. doi: 10.1038/s41416-020-0975-7
   PubMed Web of Science ®Google Scholar
• Lu Y, Wu T, Sheng Y, et al. Correlation between Claudin-18 expression and clinicopathological features and prognosis in patients with gastric cancer. J Gastrointest Oncol. 2020;11(6):1253–1260. doi: 10.21037/jgo-20-463
   PubMed Web of Science ®Google Scholar
• Rüschoff J, Hanna W, Bilous M, et al. HER2 testing in gastric cancer: a practical approach. Mod Pathol. 2012;25(5):637–650. doi: 10.1038/modpathol.2011.198
   PubMed Web of Science ®Google Scholar
• Roviello G, Catalano M, Iannone LF, et al. Current status and future perspectives in HER2 positive advanced gastric cancer. Clin Transl Oncol. 2022;24(6):981–996. doi: 10.1007/s12094-021-02760-0
   PubMed Web of Science ®Google Scholar
• Bolandi N, Derakhshani A, Hemmat N, et al. The Positive and Negative Immunoregulatory Role of B7 Family: promising Novel Targets in Gastric Cancer Treatment. Int J Mol Sci. 2021;22(19):22. doi: 10.3390/ijms221910719
   Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26(1):677–704. doi: 10.1146/annurev.immunol.26.021607.090331
   PubMed Web of Science ®Google Scholar
• Liu X, Choi MG, Kim K, et al. High PD-L1 expression in gastric cancer (GC) patients and correlation with molecular features. Pathol Res Pract. 2020;216:152881.
   PubMed Web of Science ®Google Scholar
• Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–133. doi: 10.1016/S0140-6736(18)31257-1
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients with Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: phase 2 Clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013
   PubMed Web of Science ®Google Scholar
• Ooki A, Yamaguchi K. The beginning of the era of precision medicine for gastric cancer with fibroblast growth factor receptor 2 aberration. Gastric Cancer. 2021;24(6):1169–1183. doi: 10.1007/s10120-021-01235-z
   PubMed Web of Science ®Google Scholar
• Schrumpf T, Behrens HM, Haag J, et al. FGFR2 overexpression and compromised survival in diffuse-type gastric cancer in a large central European cohort. PLoS One. 2022;17(2):e0264011. doi: 10.1371/journal.pone.0264011
   PubMed Web of Science ®Google Scholar
• Wainberg ZA, Enzinger PC, Kang YK, et al. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022;23(11):1430–1440. doi: 10.1016/S1470-2045(22)00603-9
   PubMed Web of Science ®Google Scholar
• Li K, Luo H, Huang L, et al. Microsatellite instability: a review of what the oncologist should know. Cancer Cell Int. 2020;20(1):16. doi: 10.1186/s12935-019-1091-8
   PubMed Web of Science ®Google Scholar
• Baudhuin LM, Burgart LJ, Leontovich O, et al. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer. 2005;4(3):255–265. doi: 10.1007/s10689-004-1447-6
   PubMed Web of Science ®Google Scholar
• Tanaka A, Ishikawa S, Ushiku T, et al. Frequent CLDN18-ARHGAP fusion in highly metastatic diffuse-type gastric cancer with relatively early onset. Oncotarget. 2018;9(50):29336–29350. doi: 10.18632/oncotarget.25464
   PubMedGoogle Scholar
• Arnold A, Daum S, von Winterfeld M, et al. Prognostic impact of Claudin 18.2 in gastric and esophageal adenocarcinomas. Clin Transl Oncol. 2020;22:2357–2363. doi: 10.1007/s12094-020-02380-0
   PubMed Web of Science ®Google Scholar
• Türeci O, Sahin U, Schulze-Bergkamen H, et al. A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study. Ann Oncol. 2019;30(9):1487–1495. doi: 10.1093/annonc/mdz199
   PubMed Web of Science ®Google Scholar
• Sahin U, Türeci Ö, Manikhas G, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32(5):609–619. doi: 10.1016/j.annonc.2021.02.005
   PubMed Web of Science ®Google Scholar
• Shitara K, Lordick F, Bang YJ, et al. Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2023;401(10389):1655–1668. doi: 10.1016/S0140-6736(23)00620-7
   PubMed Web of Science ®Google Scholar
• Kotzev AI, Draganov PV. Carbohydrate Antigen 19-9, Carcinoembryonic Antigen, and Carbohydrate Antigen 72-4 in Gastric Cancer: is the Old Band Still Playing? Gastrointest Tumors. 2018;5(1–2):1–13. doi: 10.1159/000488240
   PubMed Web of Science ®Google Scholar
• Shigemori T, Toiyama Y, Okugawa Y, et al. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression. Ann Surg Oncol. 2019;26:876–883.
   PubMed Web of Science ®Google Scholar
• Kushlinskii NE, Gershtein ES, Ivannikov AA, et al. Clinical Significance of Matrix Metalloproteinases in Blood Plasma of Patients with Gastric Cancer. Bull Exp Biol Med. 2019;166(3):373–376. doi: 10.1007/s10517-019-04353-y
   PubMed Web of Science ®Google Scholar
• Lu Z, Zou J, Hu Y, et al. Serological Markers Associated with Response to Immune Checkpoint Blockade in Metastatic Gastrointestinal Tract Cancer. JAMA Netw Open. 2019;2:e197621. doi: 10.1001/jamanetworkopen.2019.7621
   PubMed Web of Science ®Google Scholar
• Gantuya B, Oyuntsetseg K, Bolor D, et al. Evaluation of serum markers for gastric cancer and its precursor diseases among high incidence and mortality rate of gastric cancer area. Gastric Cancer. 2019;22(1):104–112. doi: 10.1007/s10120-018-0844-8
   PubMed Web of Science ®Google Scholar
• Oshima Y, Suzuki T, Yajima S, et al. Serum p53 antibody: useful for detecting gastric cancer but not for predicting prognosis after surgery. Surg Today. 2020;50(11):1402–1408. doi: 10.1007/s00595-020-02030-6
   PubMed Web of Science ®Google Scholar
• Qin J, Wang S, Shi J, et al. Using recursive partitioning approach to select tumor-associated antigens in immunodiagnosis of gastric adenocarcinoma. Cancer Sci. 2019;110(6):1829–1841. doi: 10.1111/cas.14013
   PubMed Web of Science ®Google Scholar
• Zan X, Chen Z, Guo Q, et al. The Association of Trefoil Factors with Gastric Cancer and Premalignant Lesions: a Cross-Sectional Population-Based Cohort Study. Cancer Epidemiol Biomarkers Prev. 2022;31:625–632.
   PubMed Web of Science ®Google Scholar
• Kanda M, Suh YS, Park DJ, et al. Serum levels of ANOS1 serve as a diagnostic biomarker of gastric cancer: a prospective multicenter observational study. Gastric Cancer. 2020;23:203–211.
   PubMed Web of Science ®Google Scholar
• Wang SM, Roth MJ, Murphy GA, et al. Serologic Profile of Antiparietal Cell Antibodies, Pepsinogens, and H. pylori and Risk of Upper Gastrointestinal Cancer: a Nested Case-Control Study in China. Cancer Epidemiol Biomarkers Prev. 2019;28:2022–2029. doi: 10.1158/1055-9965.EPI-19-0512
   PubMed Web of Science ®Google Scholar
• Yoon JH, Park YG, Nam SW, et al. The diagnostic value of serum gastrokine 1 (GKN1) protein in gastric cancer. Cancer Med. 2019;8(12):5507–5514. doi: 10.1002/cam4.2457
   PubMed Web of Science ®Google Scholar
• Chen J, Chen LJ, Zhou HC, et al. Prognostic value of matrix metalloproteinase-9 in gastric cancer: a meta-analysis. Hepatogastroenterology. 2014;61:518–524.
   PubMed Web of Science ®Google Scholar
• Ding D, Hou R, Gao Y, et al. MiR-613 inhibits gastric cancer progression through repressing brain derived neurotrophic factor. Exp Ther Med. 2018;15(2):1735–1741. doi: 10.3892/etm.2017.5546
   PubMed Web of Science ®Google Scholar
• Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res. 2017;23(8):1920–1928. doi: 10.1158/1078-0432.CCR-16-1741
   PubMed Web of Science ®Google Scholar
• Loong TH, Soon NC, Nik Mahmud NRK, et al. Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus. Biomed Rep. 2017;7(5):460–468. doi: 10.3892/br.2017.985
   PubMedGoogle Scholar
• Shikata K, Ninomiya T, Yonemoto K, et al. Optimal cutoff value of the serum pepsinogen level for prediction of gastric cancer incidence: the Hisayama Study. Scand J Gastroenterol. 2012;47(6):669–675. doi: 10.3109/00365521.2012.658855
   PubMed Web of Science ®Google Scholar
• Shimizu K, Ueda Y, Yamagishi H. Titration of serum p53 antibodies in patients with gastric cancer: a single-institute study of 40 patients. Gastric Cancer. 2005;8(4):214–219. doi: 10.1007/s10120-005-0337-4
   PubMedGoogle Scholar
• Tan EM, Zhang J. Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev. 2008;222(1):328–340. doi: 10.1111/j.1600-065X.2008.00611.x
   PubMedGoogle Scholar
• Aikou S, Ohmoto Y, Gunji T, et al. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening. Gastroenterology. 2011;141:837-845.e831–837. doi: 10.1053/j.gastro.2011.05.040
   Web of Science ®Google Scholar
• Lee HS, Jeon SW, Nomura S, et al. Screening biomarker as an alternative to endoscopy for the detection of early gastric cancer: the combination of serum trefoil factor family 3 and pepsinogen. Gastroenterol Res Pract. 2018;2018:1024074. doi: 10.1155/2018/1024074
   PubMed Web of Science ®Google Scholar
• Kanda M, Shimizu D, Fujii T, et al. Function and diagnostic value of Anosmin-1 in gastric cancer progression. Int J Cancer. 2016;138(3):721–730. doi: 10.1002/ijc.29803
   PubMed Web of Science ®Google Scholar
• di Mario F, Cavallaro LG. Non-invasive tests in gastric diseases. Dig Liver Dis. 2008;40(7):523–530. doi: 10.1016/j.dld.2008.02.028
   PubMedGoogle Scholar
• Yoon JH, Ham IH, Kim O, et al. Gastrokine 1 protein is a potential theragnostic target for gastric cancer. Gastric Cancer. 2018;21(6):956–967. doi: 10.1007/s10120-018-0828-8
   PubMed Web of Science ®Google Scholar
• Yoon JH, Choi YJ, Choi WS, et al. GKN1-miR-185-DNMT1 axis suppresses gastric carcinogenesis through regulation of epigenetic alteration and cell cycle. Clin Cancer Res. 2013;19:4599–4610. doi: 10.1158/1078-0432.CCR-12-3675
   PubMed Web of Science ®Google Scholar
• Shimura T, Dagher A, Sachdev M, et al. Urinary ADAM12 and MMP-9/NGAL complex detect the presence of gastric cancer. Cancer Prev Res (Phila). 2015;8(3):240–248. doi: 10.1158/1940-6207.CAPR-14-0229
   PubMed Web of Science ®Google Scholar
• Li F, Yoshizawa JM, Kim KM, et al. Discovery and validation of salivary extracellular RNA biomarkers for noninvasive detection of gastric cancer. Clin Chem. 2018;64(10):1513–1521. doi: 10.1373/clinchem.2018.290569
   PubMed Web of Science ®Google Scholar
• Xu F, Jiang M. Evaluation of predictive role of carcinoembryonic antigen and salivary mRNA biomarkers in gastric cancer detection. Medicine (Baltimore). 2020;99(22):e20419. doi: 10.1097/MD.0000000000020419
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhang Y, Kim Y, et al. Differential proteomic analysis of human saliva using tandem mass tags quantification for gastric cancer detection. Sci Rep. 2016;6(1):22165. doi: 10.1038/srep22165
   PubMedGoogle Scholar
• Shu J, Yu H, Li X, et al. Salivary glycopatterns as potential biomarkers for diagnosis of gastric cancer. Oncotarget. 2017;8(22):35718–35727. doi: 10.18632/oncotarget.16082
   PubMedGoogle Scholar
• Kon OL, Yip TT, Ho MF, et al. The distinctive gastric fluid proteome in gastric cancer reveals a multi-biomarker diagnostic profile. BMC Med Genomics. 2008;1(1):54. doi: 10.1186/1755-8794-1-54
   PubMedGoogle Scholar
• Huang L, Xu A. Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination. Front Med. 2017;11(1):20–31. doi: 10.1007/s11684-016-0493-4
   PubMed Web of Science ®Google Scholar
• Fan H, Li X, Li ZW, et al. Urine proteomic signatures predicting the progression from premalignancy to malignant gastric cancer. EBioMedicine. 2022;86:104340. doi: 10.1016/j.ebiom.2022.104340
   PubMed Web of Science ®Google Scholar
• Shimura T, Dayde D, Wang H, et al. Novel urinary protein biomarker panel for early diagnosis of gastric cancer. Br J Cancer. 2020;123:1656–1664.
   PubMed Web of Science ®Google Scholar
• Koopaie M, Ghafourian M, Manifar S, et al. Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls. BMC Cancer. 2022;22(1):473. doi: 10.1186/s12885-022-09570-9
   PubMed Web of Science ®Google Scholar
• Virgilio E, Proietti A, D’Urso R, et al. Elevated gastric juice carbohydrate antigen 72.4 (ca 72.4) is an independent prognostic factor of poor survival for gastric cancer patients. Anticancer Res. 2020;40(3):1691–1695. doi: 10.21873/anticanres.14121
   PubMed Web of Science ®Google Scholar
• Yang Z, Yan C, Liu W, et al. Identification of novel autoantibodies in ascites of relapsed paclitaxel-resistant gastric cancer with peritoneal metastasis using immunome protein microarrays and proteomics. Cancer Biomark. 2021;31:329–338. doi: 10.3233/CBM-203142
   PubMed Web of Science ®Google Scholar
• Park HS, Kwon WS, Park S, et al. Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer. J Immunother Cancer. 2019;7(1):268. doi: 10.1186/s40425-019-0708-8
   PubMed Web of Science ®Google Scholar
• Xiang L, Wu S, Hua Q, et al. Volatile organic compounds in human exhaled breath to diagnose gastrointestinal cancer: a meta-analysis. Front Oncol. 2021;11:606915.
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Shimura T, Yamada T, et al. A novel urinary microRNA biomarker panel for detecting gastric cancer. J Gastroenterol. 2019;54(12):1061–1069. doi: 10.1007/s00535-019-01601-w
   PubMed Web of Science ®Google Scholar
• Qiao SX, Yuan M, Liu YL, et al. Detection of gastric cancer and premalignant lesions by novel marker glycoprotein 87 using monoclonal antibody Adnab-9. Cancer Epidemiol Biomarkers Prev. 2003;12:1095–1099.
   PubMed Web of Science ®Google Scholar
• Pan Y, Zheng Y, Yang J, et al. A new biomarker for the early diagnosis of gastric cancer: gastric juice- and serum-derived SNCG. Future Oncol. 2022;18(28):3179–3190. doi: 10.2217/fon-2022-0253
   PubMed Web of Science ®Google Scholar
• Cui L, Zhang X, Ye G, et al. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer. Cancer. 2013;119(9):1618–1626. doi: 10.1002/cncr.27903
   PubMed Web of Science ®Google Scholar
• Shao Y, Ye M, Li Q, et al. LncRNA-RMRP promotes carcinogenesis by acting as a miR-206 sponge and is used as a novel biomarker for gastric cancer. Oncotarget. 2016;7(25):37812–37824. doi: 10.18632/oncotarget.9336
   PubMedGoogle Scholar
• Nakanishi K, Kanda M, Umeda S, et al. The levels of SYT13 and CEA mRnas in peritoneal lavages predict the peritoneal recurrence of gastric cancer. Gastric Cancer. 2019;22(6):1143–1152. doi: 10.1007/s10120-019-00967-3
   PubMed Web of Science ®Google Scholar
• Kanda M, Shimizu D, Tanaka H, et al. Significance of SYT8 for the detection, prediction, and treatment of peritoneal metastasis from gastric cancer. Ann Surg. 2018;267(3):495–503. doi: 10.1097/SLA.0000000000002096
   PubMed Web of Science ®Google Scholar
• Kanda M, Shimizu D, Tanaka H, et al. Synaptotagmin XIII expression and peritoneal metastasis in gastric cancer. Br J Surg. 2018;105(10):1349–1358. doi: 10.1002/bjs.10876
   PubMed Web of Science ®Google Scholar
• Kanda M, Kasahara Y, Shimizu D, et al. Amido-bridged nucleic acid-modified antisense oligonucleotides targeting SYT13 to treat peritoneal metastasis of gastric cancer. Mol Ther Nucleic Acids. 2020;22:791–802. doi: 10.1016/j.omtn.2020.10.001
   PubMedGoogle Scholar
• Huang L, Zhu Y, Xu C, et al. Noninvasive diagnosis of gastric cancer based on breath analysis with a tubular surface-enhanced raman scattering sensor. ACS Sens. 2022;7:1439–1450. doi: 10.1021/acssensors.2c00146
   PubMed Web of Science ®Google Scholar
• Xu ZQ, Broza YY, Ionsecu R, et al. A nanomaterial-based breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer. 2013;108(4):941–950. doi: 10.1038/bjc.2013.44
   PubMed Web of Science ®Google Scholar
• Amal H, Shi DY, Ionescu R, et al. Assessment of ovarian cancer conditions from exhaled breath. Int J Cancer. 2015;136:E614–622. doi:10.1002/ijc.29166
   PubMed Web of Science ®Google Scholar
• Kumar S, Huang J, Abbassi-Ghadi N, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg. 2015;262(6):981–990. doi: 10.1097/SLA.0000000000001101
   PubMed Web of Science ®Google Scholar
• Durán-Acevedo CM, Jaimes-Mogollón AL, Gualdrón-Guerrero OE, et al. Exhaled breath analysis for gastric cancer diagnosis in Colombian patients. Oncotarget. 2018;9(48):28805–28817. doi: 10.18632/oncotarget.25331
   PubMedGoogle Scholar
• Schuermans VNE, Li Z, Jongen A, et al. Pilot study: detection of gastric cancer from exhaled air analyzed with an electronic nose in Chinese patients. Surg Innov. 2018;25(5):429–434. doi: 10.1177/1553350618781267
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wu H, Chong W, et al. Liquid biopsy in gastric cancer: predictive and prognostic biomarkers. Cell Death Dis. 2022;13(10):903. doi: 10.1038/s41419-022-05350-2
   PubMed Web of Science ®Google Scholar
• Ma S, Zhou M, Xu Y, et al. Clinical application and detection techniques of liquid biopsy in gastric cancer. Mol Cancer. 2023;22(1):7. doi: 10.1186/s12943-023-01715-z
   PubMed Web of Science ®Google Scholar
• Kanda M, Shimizu D, Nakamura S, et al. Blockade of CHRNB2 signaling with a therapeutic monoclonal antibody attenuates the aggressiveness of gastric cancer cells. Oncogene. 2021;40(36):5495–5504. doi: 10.1038/s41388-021-01945-9
   PubMed Web of Science ®Google Scholar
• Kanda M, Shimizu D, Sawaki K, et al. Therapeutic monoclonal antibody targeting of neuronal pentraxin receptor to control metastasis in gastric cancer. Mol Cancer. 2020;19(1):131. doi: 10.1186/s12943-020-01251-0
   PubMed Web of Science ®Google Scholar